Performance of the Resolute Zotarolimus-Eluting Stent in Small Vessels

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F14%3A43908648" target="_blank" >RIV/00216208:11120/14:43908648 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/14:N0000003

Výsledek na webu

<a href="http://dx.doi.org/10.1002/ccd.25485" target="_blank" >http://dx.doi.org/10.1002/ccd.25485</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ccd.25485" target="_blank" >10.1002/ccd.25485</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Performance of the Resolute Zotarolimus-Eluting Stent in Small Vessels

Popis výsledku v původním jazyce

Background: Drug eluting stents for the treatment of small vessel coronary artery disease have traditionally yielded inferior clinical outcomes compared to the use of DES in large vessels. The benefit of the second-generation Resolute zotarolimus-elutingstent (R-ZES) in small vessels was examined. Methods: Two-year clinical outcomes from five combined R-ZES studies were compared between patients with small (reference vessel diameter [RVD] <= 2.5 mm; n = 1,956) and large (RVD >2.5 mm; n = 3174) vessels.Results: Despite a higher incidence of comorbidities in the small vessel group, there was no significant difference in target lesion failure (TLF) (10.1% vs. 8.7%; P = 0.54) at 2 years. When the subgroup of patients with diabetes was examined (n = 1,553) there was no significant difference in 2-year TLF in small compared to large vessels (11.2% vs. 11.1%; P = 0.17). Similarly, within the small vessel cohort, no significant difference was seen regarding TLF at 2 years between people with

Název v anglickém jazyce

Performance of the Resolute Zotarolimus-Eluting Stent in Small Vessels

Popis výsledku anglicky

Background: Drug eluting stents for the treatment of small vessel coronary artery disease have traditionally yielded inferior clinical outcomes compared to the use of DES in large vessels. The benefit of the second-generation Resolute zotarolimus-elutingstent (R-ZES) in small vessels was examined. Methods: Two-year clinical outcomes from five combined R-ZES studies were compared between patients with small (reference vessel diameter [RVD] <= 2.5 mm; n = 1,956) and large (RVD >2.5 mm; n = 3174) vessels.Results: Despite a higher incidence of comorbidities in the small vessel group, there was no significant difference in target lesion failure (TLF) (10.1% vs. 8.7%; P = 0.54) at 2 years. When the subgroup of patients with diabetes was examined (n = 1,553) there was no significant difference in 2-year TLF in small compared to large vessels (11.2% vs. 11.1%; P = 0.17). Similarly, within the small vessel cohort, no significant difference was seen regarding TLF at 2 years between people with

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Catheterization and Cardiovascular Interventions

ISSN

1522-1946

e-ISSN

—

Svazek periodika

84

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

17-23

Kód UT WoS článku

000337970100007

EID výsledku v databázi Scopus

—